AR005339A1 - Anticuerpos monoclonales antiidiotipos (ab2) y sus usos - Google Patents
Anticuerpos monoclonales antiidiotipos (ab2) y sus usosInfo
- Publication number
- AR005339A1 AR005339A1 ARP970100004A ARP970100004A AR005339A1 AR 005339 A1 AR005339 A1 AR 005339A1 AR P970100004 A ARP970100004 A AR P970100004A AR P970100004 A ARP970100004 A AR P970100004A AR 005339 A1 AR005339 A1 AR 005339A1
- Authority
- AR
- Argentina
- Prior art keywords
- monoclonal antibodies
- antiidiotipes
- idiotypes
- mabs
- immunotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se relaciona con la rama de ina Inmunología y en particular con la selección y uso de anticuerpos monoclonales (AcM)antiidiotipos (AB2) de tipo IgG, que poseen la característica de presentar una alta conectividadidiotípic a y reconocimiento de los linfocitos B y T humanos,moléculas que de manera escencial participan en el desarrollo de la respuesta inmune por lo que pueden ser utilizados en la inmunoterapia de las enfermedadesautoinmunes, infecciosas ycáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9600235.7A GB9600235D0 (en) | 1996-01-05 | 1996-01-05 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR005339A1 true AR005339A1 (es) | 1999-04-28 |
Family
ID=10786682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100003A AR005338A1 (es) | 1996-01-05 | 1997-01-02 | Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios |
| ARP970100004A AR005339A1 (es) | 1996-01-05 | 1997-01-02 | Anticuerpos monoclonales antiidiotipos (ab2) y sus usos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970100003A AR005338A1 (es) | 1996-01-05 | 1997-01-02 | Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6242438B1 (es) |
| EP (1) | EP0871623B1 (es) |
| JP (2) | JP3123611B2 (es) |
| KR (1) | KR100275402B1 (es) |
| AP (1) | AP709A (es) |
| AR (2) | AR005338A1 (es) |
| AT (1) | ATE232526T1 (es) |
| AU (1) | AU708282B2 (es) |
| BG (1) | BG102589A (es) |
| BR (1) | BR9612412A (es) |
| CA (1) | CA2237189C (es) |
| CO (1) | CO4750815A1 (es) |
| CZ (1) | CZ209398A3 (es) |
| DE (1) | DE69626220T2 (es) |
| DK (1) | DK0871623T3 (es) |
| DZ (1) | DZ2155A1 (es) |
| ES (1) | ES2190486T3 (es) |
| GB (1) | GB9600235D0 (es) |
| HR (1) | HRP970006A2 (es) |
| HU (1) | HUP9903590A3 (es) |
| IL (2) | IL145324A0 (es) |
| IS (1) | IS1876B (es) |
| MA (1) | MA26417A1 (es) |
| NO (1) | NO311838B1 (es) |
| NZ (1) | NZ324712A (es) |
| OA (1) | OA10863A (es) |
| PE (1) | PE29798A1 (es) |
| PL (1) | PL185723B1 (es) |
| RU (1) | RU2158264C2 (es) |
| SI (1) | SI0871623T1 (es) |
| SK (1) | SK89598A3 (es) |
| TN (1) | TNSN96174A1 (es) |
| TR (1) | TR199801268T2 (es) |
| TW (1) | TW472054B (es) |
| UY (1) | UY24429A1 (es) |
| WO (1) | WO1997025322A1 (es) |
| YU (1) | YU71496A (es) |
| ZA (1) | ZA9747B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9714129D0 (en) * | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
| WO1999019297A1 (en) * | 1997-10-15 | 1999-04-22 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| DE69830615T2 (de) | 1997-12-04 | 2006-03-16 | Sankyo Co., Ltd. | Alicyclische acylierte heterocyclenderivate |
| GB9821898D0 (en) * | 1998-10-08 | 1998-12-02 | Pfizer Ltd | Heterocycles |
| NZ523310A (en) * | 2000-06-12 | 2005-07-29 | Univ Rochester | Tachykinin receptor antagonist to block receptors NK1, NK2, and NK3 and treat symptoms of hormonal variation |
| US6642226B2 (en) * | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| GB0130261D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Lactams as tachykinin antagonists |
| PL373410A1 (en) * | 2002-02-01 | 2005-08-22 | F.Hoffman-La Roche Ag | Substituted indoles as alpha-1 agonists |
| US7674783B2 (en) * | 2002-11-22 | 2010-03-09 | Dimera Inc. | Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease |
| CA2509406C (en) * | 2002-12-23 | 2012-07-03 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| TW200508221A (en) | 2003-06-13 | 2005-03-01 | Astrazeneca Ab | New azetidine compounds |
| EP1498123A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Emulsifying systems containing azetidine derivatives |
| CA2570637A1 (en) | 2004-06-24 | 2006-02-02 | Wenqing Yao | N-substituted piperidines and their use as pharmaceuticals |
| JP2008504279A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
| ES2350647T3 (es) | 2005-03-08 | 2011-01-25 | Janssen Pharmaceutica Nv | Derivados de diaza-espiro-[4.4]-nonano como antagonistas de neuroquininas (nk1). |
| AR057828A1 (es) | 2005-09-29 | 2007-12-19 | Astrazeneca Ab | Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica |
| US8106208B2 (en) | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
| KR20090112722A (ko) | 2007-01-24 | 2009-10-28 | 글락소 그룹 리미티드 | 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물 |
| RU2402546C2 (ru) * | 2008-11-20 | 2010-10-27 | Федеральное государственное учреждение "27 Научный центр Министерства Обороны Российской Федерации" | Способ получения метил 4-[(3,4-дихлорфенил)ацетил]-3-[(1-пирролидинил)метил]-1-пиперазинкарбоксилата |
| WO2010071575A1 (en) * | 2008-12-16 | 2010-06-24 | Astrazeneca Ab | Quaternary piperidine derivatives and uses thereof |
| KR20120034617A (ko) * | 2009-04-22 | 2012-04-12 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 억제제로서의 아제티디닐 다이아미드 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226998A (en) * | 1974-09-26 | 1980-10-07 | Ciba-Geigy Corporation | 1-Benzothiepin-4-carboxamides |
| GB1600880A (en) * | 1978-05-23 | 1981-10-21 | Lilly Industries Ltd | Pharmaceutical compositions comprising hydantoin derivatives |
| SU1032752A1 (ru) * | 1981-08-14 | 1990-11-07 | Институт биохимии АН ЛитССР | Калиева соль 4-(пиперидиназо)-N-ацетилбензолсульфамида, обладающа противовоспалительной активностью |
| SE8904298D0 (sv) * | 1989-12-21 | 1989-12-21 | Astra Ab | New compounds |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical compositions containing them |
| FR2676055B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| CA2160462C (en) | 1993-05-06 | 1998-12-15 | Timothy P. Burkholder | Substituted pyrrolidin-3-yl-alkyl-piperidines useful as tachykinin antagonists |
| GB9315808D0 (en) * | 1993-07-30 | 1993-09-15 | Merck Sharp & Dohme | Therapeutic agents |
| DE69504300T2 (de) * | 1994-01-13 | 1999-04-29 | Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire | Gem-bissubstituierte azazyclische tachykinin-antagonisten |
| FR2719311B1 (fr) * | 1994-03-18 | 1998-06-26 | Sanofi Sa | Composés antagonistes sélectifs du récepteur NK3 humain et leur utilisation comme médicaments et outils de diagnostic. |
| FR2717804B1 (fr) | 1994-03-25 | 1996-06-21 | Sanofi Sa | Sels de composés hétéroaromatiques azotés substitués, procédé pour leur préparation et compositions pharmaceutiques en contenant. |
| TW432061B (en) * | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
| CA2241827C (en) | 1995-12-20 | 2002-04-30 | Hoechst Marion Roussel, Inc. | Novel substituted 4-(1h-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases |
| GB9601202D0 (en) * | 1996-01-22 | 1996-03-20 | Pfizer Ltd | Piperidones |
| GB9812037D0 (en) * | 1998-06-04 | 1998-07-29 | Pfizer Ltd | Piperidones |
| GB9821898D0 (en) * | 1998-10-08 | 1998-12-02 | Pfizer Ltd | Heterocycles |
-
1996
- 1996-01-05 GB GBGB9600235.7A patent/GB9600235D0/en active Pending
- 1996-12-06 TW TW085115107A patent/TW472054B/zh not_active IP Right Cessation
- 1996-12-09 KR KR1019980705159A patent/KR100275402B1/ko not_active Expired - Fee Related
- 1996-12-09 DK DK96943119T patent/DK0871623T3/da active
- 1996-12-09 HU HU9903590A patent/HUP9903590A3/hu unknown
- 1996-12-09 IL IL14532496A patent/IL145324A0/xx unknown
- 1996-12-09 JP JP09520769A patent/JP3123611B2/ja not_active Expired - Fee Related
- 1996-12-09 PL PL96327665A patent/PL185723B1/pl not_active IP Right Cessation
- 1996-12-09 SK SK895-98A patent/SK89598A3/sk unknown
- 1996-12-09 BR BR9612412A patent/BR9612412A/pt not_active Application Discontinuation
- 1996-12-09 RU RU98114667/04A patent/RU2158264C2/ru not_active IP Right Cessation
- 1996-12-09 NZ NZ324712A patent/NZ324712A/xx unknown
- 1996-12-09 SI SI9630590T patent/SI0871623T1/xx unknown
- 1996-12-09 AU AU11950/97A patent/AU708282B2/en not_active Ceased
- 1996-12-09 DE DE69626220T patent/DE69626220T2/de not_active Expired - Fee Related
- 1996-12-09 CZ CZ982093A patent/CZ209398A3/cs unknown
- 1996-12-09 US US09/297,736 patent/US6242438B1/en not_active Expired - Fee Related
- 1996-12-09 ES ES96943119T patent/ES2190486T3/es not_active Expired - Lifetime
- 1996-12-09 WO PCT/EP1996/005613 patent/WO1997025322A1/en not_active Ceased
- 1996-12-09 IL IL12430996A patent/IL124309A/en not_active IP Right Cessation
- 1996-12-09 TR TR1998/01268T patent/TR199801268T2/xx unknown
- 1996-12-09 EP EP96943119A patent/EP0871623B1/en not_active Expired - Lifetime
- 1996-12-09 AT AT96943119T patent/ATE232526T1/de not_active IP Right Cessation
- 1996-12-09 CA CA002237189A patent/CA2237189C/en not_active Expired - Fee Related
- 1996-12-19 AP APAP/P/1996/000901A patent/AP709A/en active
- 1996-12-27 PE PE1996000960A patent/PE29798A1/es not_active Application Discontinuation
- 1996-12-31 YU YU71496A patent/YU71496A/sr unknown
- 1996-12-31 TN TNTNSN96174A patent/TNSN96174A1/fr unknown
- 1996-12-31 MA MA24446A patent/MA26417A1/fr unknown
- 1996-12-31 DZ DZ960200A patent/DZ2155A1/fr active
-
1997
- 1997-01-02 AR ARP970100003A patent/AR005338A1/es unknown
- 1997-01-02 AR ARP970100004A patent/AR005339A1/es unknown
- 1997-01-03 ZA ZA9747A patent/ZA9747B/xx unknown
- 1997-01-03 HR HR9600235.7A patent/HRP970006A2/xx not_active Application Discontinuation
- 1997-01-03 UY UY24429A patent/UY24429A1/es not_active Application Discontinuation
- 1997-01-07 CO CO97000263A patent/CO4750815A1/es unknown
-
1998
- 1998-05-28 IS IS4760A patent/IS1876B/is unknown
- 1998-05-29 OA OA9800066A patent/OA10863A/en unknown
- 1998-06-09 NO NO19982651A patent/NO311838B1/no unknown
- 1998-06-30 BG BG102589A patent/BG102589A/xx unknown
-
2000
- 2000-05-10 JP JP2000136658A patent/JP3254205B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR005339A1 (es) | Anticuerpos monoclonales antiidiotipos (ab2) y sus usos | |
| ES2124533T3 (es) | Anticuerpos monoclonales inmunoestimulantes. | |
| ATE113845T1 (de) | Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung. | |
| DK0796280T3 (da) | Murint monoklonalt anti-idiotypisk antistof 3H1 | |
| NO933179D0 (no) | Anti-idiotype antistoffer overfor human melanoma-assosiert proteoglykanantigen | |
| DK0460167T3 (da) | Humaniserede antistoffer | |
| ES2075327T3 (es) | Metodo para multiplicar linfocitos de sangre periferica humana in vitro que producen anticuerpos monoclonales especificos para un antigeno. | |
| DK0432249T3 (da) | Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf | |
| DK101888A (da) | Immunmodulerende midler og anvendelse af disse | |
| DK0474691T3 (da) | Monoklonale antistoffer til induktion af tolerance | |
| ATE171473T1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 | |
| FI900230A7 (fi) | Anti-idiotyyppisiä vasta-aineita ihmisen suurimolekyylipainoisten mela noomaan liittyvien antigeenien vasta-aineille | |
| CU22585A1 (es) | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. | |
| ATE119203T1 (de) | Monoklonale antikörper von mäusen gegen das gp41 protein von menschlichem immunmangelsyndrom- virus. | |
| ES2180052T3 (es) | Anticuerpos especificos del cancer de prostata para inmunodeteccion e inmunoterapia. | |
| NO972522L (no) | Monoklonale antistoffer med immunoundertrykkende aktivitet | |
| DK0825256T3 (da) | Hybridcelle og dens anvendelse til fremstilling af et lægemiddel til inducering af en tumorimmunitet | |
| Sun et al. | Localization of epitopes for monoclonal antibodies directed against the adult rat skeletal muscle sodium channel (rSkM1) using polymerase chain reaction, fusion proteins, and western blotting | |
| DE69111429D1 (de) | Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen. | |
| FI895829A7 (fi) | Ihmisen monoklonaaliset vasta-aineet rabiesvirusta vastaan | |
| DK616989A (da) | Humane monoklonale antistoffer, der specifikt genkender rabiesvirusceller, celler, der prducerer denne virus, formuleringer, der indeholder virusen, samt fremstilling af disse antistoffer | |
| NO900216L (no) | Anti-idiotype antistoff mot anti-human melanom-assosiert antigen med hoey molekylvekt. | |
| CU22500A1 (es) | Anticuerpos monoclonales anti-gangliosidos, anticuerpos monoclonales antiidiotipos, hibridomas productores y procedimiento de obtención de los mismos | |
| DK373389D0 (da) | Fremgangsmaade til selektion af anti-idiotype antistoffer og anvendelse af disse til diagnostiske og terapeutiske formaal |